stockrowRenalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024.
Follow RNLXY
Alert me
Renalytix plc - Sponsored ADR (RNLXY) EV/Sales
As of 4 November 2026, Renalytix plc - Sponsored ADR (RNLXY) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 0.0× (June 2021) to 736× (July 2021); the current reading is higher than 26% of that period. That is in line with the Health Information Services industry median of 2.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.5× | (35.28%) |
| FY2024 | 5.4× | (82.19%) |
| FY2023 | 30.5× | 62.84% |
| FY2022 | 18.7× | (97.11%) |
| FY2021 | 648× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 6.0× | 11.07% |
| Jun 2024 | 5.4× | (70.22%) |
| Mar 2024 | 18.2× | 115.63% |
| Dec 2023 | 8.5× | (61.21%) |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ACON Aclarion, Inc. compare | −98.0× |
| HLTHQ Cue Health Inc. compare | −1.1× |
| ZCMD Zhongchao Inc. compare | −0.5× |
| BEAT HeartBeam, Inc. compare | n/m |
| DRIO DarioHealth Corp. compare | 2.5× |
| RNLXY Renalytix plc - Sponsored ADR | 2.8× |
| BFRG Bullfrog AI Holdings Inc. compare | 6.0× |
| MGRX Mangoceuticals, Inc. compare | 9.6× |
| ONMD OneMedNet Corporation compare | 17.1× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)